HENGRUI THERAPEUTICS, INC.
Home
Who We Are
R&D
News
News and Buzz
Scientific and Medical Releases
Partners
Careers
Contact
News and Buzz
COMMITMENT...MATTERS
SCIENTIFIC & MEDICAL PUBLICATIONS
2018 EHA Meeting - TG Therapeutics, Inc. Presents TG-1701 or SHR-1459, a novel, orally available, and covalently-bound BTK inhibitor
2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "
A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients."
2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial."
2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma."
2018 ASCO Meeting - Hengrui Medicine presents an abstract titled "Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma."
2017 ASCO Meeting - Hengrui Medicine presents an abstract titled "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors."
2017 Journal of Clinical Oncology - "Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer"
2017 European Journal of Pharmaceutical Sciences - "Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer"
Home
Who We Are
R&D
News
News and Buzz
Scientific and Medical Releases
Partners
Careers
Contact
News and Buzz